Nektar Therapeutics falls on quarterly revenue miss
14/08/2026 12:41
BUZZ-Nektar Therapeutics falls on quarterly revenue miss ** Shares of drug developer Nektar Therapeutics NKTR.O down 3.6% at $73.20 premarket
** Co reports Q2 rev of $10.1 mln vs. $11.2 mln yr earlier
** Rev est. $10.4 mln - LSEG data
** NKTR's lead experimental drug, rezpegaldesleukin, is in late-stage development for the treatment of a type of skin disease called atopic dermatitis
** Co says it has cash runway that extends into Q3 2028
** Up to last close, stock up 79.6% YTD
(Reporting by Christy Santhosh)
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says